Ascletis Pharma Inc (2VJ) — Cash Flow-to-Debt Ratio
Ascletis Pharma Inc (2VJ) has a Cash Flow-to-Debt Ratio of -0.37x as of June 2023, meaning its operating cash flow of €-33.98 Million could theoretically repay 0% of its total liabilities (€90.79 Million) in one year. See Ascletis Pharma Inc (2VJ) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Ascletis Pharma Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Ascletis Pharma Inc across 10 annual periods. Also explore Ascletis Pharma Inc (2VJ) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Ascletis Pharma Inc (2016–2025)
Year-by-year debt coverage analysis for Ascletis Pharma Inc. For market capitalisation and broader financial context, see 2VJ market cap.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.15x | €-416.78 Million | €132.26 Million | ▼ -46.1% |
| 2024 | -2.16x | €-341.58 Million | €158.41 Million | ▼ -43.5% |
| 2023 | -1.50x | €-223.79 Million | €148.94 Million | ▼ -23.6% |
| 2022 | -1.22x | €-142.45 Million | €117.16 Million | ▲ +16.5% |
| 2021 | -1.46x | €-146.93 Million | €100.89 Million | ▼ -46.5% |
| 2020 | -0.99x | €-84.91 Million | €85.42 Million | ▼ -36.6% |
| 2019 | -0.73x | €-74.34 Million | €102.17 Million | ▲ +24.5% |
| 2018 | -0.96x | €-96.59 Million | €100.19 Million | ▲ +40.9% |
| 2017 | -1.63x | €-198.06 Million | €121.42 Million | ▼ -1559.8% |
| 2016 | -0.10x | €-12.50 Million | €127.18 Million | — |